Washington DC, July 24, 2013 – An M&A team from Patton Boggs LLP headed by Geoff Davis, a partner in the firm’s Washington DC office and Mark Goldschmidt, a partner in the firm’s Denver office recently represented Intezyne Technologies, a leader in the use of nanotechnology in the development of cancer treatment, in its strategic acquisition of target Niiki Pharma, significantly expanding Intezyne’s portfolio of cancer drugs and market valuation.
The complex acquisition involved highly creative approaches in a number of areas, including a novel solution to stock valuation, complicated negotiations with Niiki creditors, and a unique earnout plan contingent on the success of Niiki drugs at key milestones in the clinical phases of approval. Through the acquisition, Intezyne became a development-stage company with two compounds in early and mid-stage clinical development. Niiki Pharma now has a more stable funding platform and synergistic technologies and research. Most importantly, the acquisition will benefit cancer treatment by enabling Intezyne to offer treatment options for certain types of cancer for which no treatment currently exists.
The effort engaged a cross-section of firm practices seamlessly, including the insights of attorneys from the firm’s corporate, securities, tax, ERISA and employee benefits, FDA and real estate practices. Partners Carey Nuttall, Michael Curto, Sean Clancy, Sven Collins, and Victor Pregel and associates Shawn Turner, Colleen O’Boyle, Kim Caccavaro, Michi Tsuda, and paralegal Nikol Dor served as integral members of the Patton Boggs team advising on the transaction and positioning the firm for future client successes in the field on oncology biologics and pharmaceuticals.